An inflammaging drug cut a key inflammatory signal by up to 98% in early testing — Phase 2 will tell
Edited by Samael A. Tejada, Founder & Editor-in-Chief
·Tip: press play, then lock your phone or switch apps — the article keeps reading.
BioAge's oral NLRP3 inhibitor BGE-102 suppressed the inflammatory signal IL-1β by up to 98% in Phase 1 testing and cut hsCRP by a median 86% (company-reported). A fully enrolled Phase 2 trial in about 160 adults reads out in late 2026. Biomarker movement is not proof of clinical benefit.
Inflammaging drug development lives or dies on one distinction: moving an inflammation marker is easy to show; making people healthier is not. BGE-102 has cleared the first bar, loudly. The second bar is what Phase 2 is for.
Why does an inflammation drug belong in a mitochondria publication?
Because one of the NLRP3 inflammasome's best-known triggers sits inside mitochondria. When mitochondria are damaged, they release signals — including mitochondrial DNA and reactive oxygen species — that help switch NLRP3 on, driving production of IL-1β, a master inflammatory messenger. Blocking NLRP3 is therefore one of the more direct attempts to interrupt a mitochondria-to-inflammation pathway in human aging.
What has actually been shown in people?
In the completed Phase 1 single- and multiple-dose trial, BGE-102 achieved up to 98% suppression of IL-1β at trough in an ex vivo whole-blood assay, with median hsCRP reductions of 86% from baseline at both 60 mg and 120 mg once daily, and a tolerability profile the company describes as similar to placebo. The Phase 2 QUELL-CV trial — randomised, double-blind, placebo-controlled, testing 30, 60 and 90 mg daily over 12 weeks in about 160 adults with obesity and elevated baseline inflammation — has completed enrollment; its primary endpoint is percent change in hsCRP, with topline data expected in the fourth quarter of 2026. A second Phase 2, QUELL-DME in diabetic macular edema, dosed its first participant in September 2026, with results expected in the second half of 2027.
What should readers not conclude?
That an anti-aging drug has arrived. Every number above is a biomarker reported by the company developing the drug; hsCRP and IL-1β are signals, not outcomes. No trial has yet shown BGE-102 prevents cardiovascular events, extends healthspan, or improves how people feel or function — and chronic inflammasome suppression carries theoretical infection-risk questions that only larger, longer trials can answer.
Frequently asked questions
What is the NLRP3 inflammasome?
A protein complex inside immune cells that, when triggered — by infection signals, crystals, or distress signals from damaged mitochondria — activates production of the inflammatory messenger IL-1β.
What is inflammaging?
The chronic, low-grade inflammation that rises with age and is linked to cardiovascular, metabolic and neurodegenerative disease. Mitochondrial decline is one of its proposed drivers.
When will we know if BGE-102 works?
Phase 2 QUELL-CV biomarker results are expected in the fourth quarter of 2026. Outcome trials, if the program advances, would take years longer.
Where the evidence stands
- Established: The NLRP3 inflammasome drives IL-1β production, is activated by mitochondrial distress signals among other triggers, and contributes to age-related inflammatory disease biology.
- Preliminary: BGE-102's effects: company-reported Phase 1 biomarker data (up to 98% IL-1β suppression; median 86% hsCRP reduction); Phase 2 trials are underway with biomarker primary endpoints.
- Absent: Evidence that BGE-102 improves clinical outcomes — events, function, or lifespan — in any population.
Join the discussion
To get the conversation started: What questions does this story raise for you? Share them below — every comment is reviewed by our moderators before it appears.
Community discussion only — not medical advice. Every comment is reviewed by our moderators before it appears. Sign in with Google or a free Hyvor account to join in.